Cardio IQ Advanced Lipid Panel Plus and Inflammation Panel
Measuring Lipid Subclasses using Ion Mobility
The way most doctors test for heart disease is with a lipid panel. It helps detect what HDL (good) and LDL (bad) cholesterol are, so hopefully you can reduce your risk of a possible cardiac event such as a heart attack. Nearly half of all heart attack patients were found to have no prior risk which would indicate they were heading toward an attack.
Quest Diagnostics offers advanced cardiovascular tests that help provide a more accurate and individualized picture of risk. The tests look beyond just HDL and LDL cholesterol to identify undiagnosed (or additional) risk.
These advanced cardiovascular tests, along with your lipid panel, will provide more information that you and your doctor can use to understand your complete cardiovascular health.
Lipid Subclasses as measured by Ion Mobility Technology
Knowing what particles make up your LDL and HDL cholesterol may be important. Ion Mobility Technology provides subclass separation that will allow your healthcare provider to identify your cardiovascular risk over time. Following the change in your lipid profile as you respond to diet, exercise and possible medication to reduce your cardiovascular risk is important. Ion Mobility provides the opportunity to determine if treatment is working and if not, optimize the aggressiveness of therapy to hopefully make a difference that can be seen in the Ion Mobility measurement and graphical representation of your LDL and HDL particles.
Cardio IQ™ Lipoprotein Fractionation, Ion Mobility
Cardio IQ™ Lipid Panel
Cardio IQ™ Direct LDL
Cardio IQ™ Apolipoprotein Evaluation
Cardio IQ™ Lipoprotein (A)
- Apo B is a direct measurement of the number of lipoprotein particles, including LDL (“bad cholesterol”), IDL, and VLDL
- A high Apo B number indicates increased risk for heart disease
- Certain medications, improved eating habits, increased physical activity, and loss of body fat are some ways to
improve Apo B
Lipoprotein (A) - Lp(a)
- High levels of Lp(a) are associated with increased risk of cardiovascular disease and stroke
- Lp(a) levels may be influenced by genetics. Diet and exercise have limited to no effect on lowering Lp(a); however, certain
medications can lower levels
Cardio IQ® Apolipoprotein Evaluation - (APOLIPOPROTEIN A1, APOLIPOPROTEIN B and APOLIPOPROTEIN B/A1 RATIO)
- Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.
- High levels of C-Reactive Protein (CRP) indicate inflammation due to infection or tissue injury
- Modestly elevated CRP levels may be associated with increased heart disease risk. If both CRP and Lp-PLA2 levels are
high, your risk for a heart attack or stroke increases significantly
- Certain medications and food may have anti-inflammatory benefits
- High levels of Lp-PLA2 can predict risk of a heart attack or stroke
- When both Lp-PLA2 levels and systolic blood pressure are high, stroke risk increases significantly
- Certain medications can reduce levels of Lp-PLA2